ChemoMetec: The Guidance Says Turn, Consumables Say Not Yet

A Danish company that builds instruments to count and analyze living cells just asked investors to believe in a comeback. ChemoMetec (Copenhagen: CHEMM; traded over the counter in the US) reported a subdued 2025/26 — revenue up 3% to DKK 511.1 million, its recurring consumables sales down 4% — and then guided the new 2026/27 financial year to revenue of DKK 545–575 million and EBITDA of DKK 300–315 million. At the midpoint that is roughly 10% growth. The shares still trade at a premium of around 40–45 times last year's profit, so the market is not handing you a discount for the doubt. The real question is whether this guidance is a genuine turn in the business or a promise that has outrun the proof.

What one soft year contained

ChemoMetec is a razor-and-blades operation inside biotech. It sells automated cell counters — the instruments — used in research, cell and gene therapy, and bioprocessing, then earns recurring money as customers spend on its specialized counting reagents and services. Consumables alone made up about 45% of revenue at the half-year, which is why how that recurring slice behaves matters more than any single new instrument sale.

By the numbers, fiscal 2025/26 (July 2025 through June 2026) was a bad year wearing a decent margin. Revenue grew just 3% as reported, though about 7% at constant exchange rates; EBITDA rose from DKK 258.0 million to DKK 281.3 million, pushing the margin to roughly 55%; net profit came to DKK 201.8 million. The company ended the year having already trimmed its full-year outlook in May — from roughly DKK 565–580 million of revenue down to DKK 505–525 million — and it landed at 511.1 million, inside the reduced range.

Two forces produced the shortfall, and neither was pure operating weakness. The U.S. dollar fell about 10% against the Danish krone over the year, and a historically long U.S. government shutdown froze demand for a stretch in late 2025. On top of that, ChemoMetec is deliberately walking away from its old animal-semen, beer, and milk counting market, a small legacy line that dropped sharply as management refocused on drug manufacturing. The U.S. and Canada contribute more than half of revenue, so those blows hit the biggest number on the ledger.

What the new guidance really asks

Against that backdrop, the FY2026/27 guidance — DKK 545–575 million of revenue and DKK 300–315 million of EBITDA — is a re-acceleration claim. It pushes growth from a reported 3% back toward a mid-point of about 10%, and it keeps the EBITDA margin near 55%. Management's stated engines are the newer XcytoMatic automation platform, the replacement of the older NC-200 counter with the NC-203, and partnerships that link its instruments into the automated bioprocessing workflow. In other words: the company is betting last year's trouble was a transition between product generations and a currency shock, not a loss of demand.

There is real evidence behind that claim. Sales of XcytoMatic instruments more than doubled, from DKK 27.7 million to DKK 61.8 million, and overall instrument sales rose 13% while services rose 4%. In the third quarter, XcytoMatic sales roughly quadrupled year over year, and Europe and the rest of the world grew 14% and 21% respectively for the year. The automation story looks like a product cycle, not a marketing line.

The counterweight is the recurring base. Consumables fell 4% for the year, and the decline was sharpest where it matters most to future proof: in the U.S., third-quarter consumables dropped 19% year over year as approved cell-therapy programs treated fewer patients and some customers pulled back. A new instrument installed today does not generate its reagent revenue until the customer actually runs it at scale, so ChemoMetec has built up a stock of fresh machines whose "blade" revenue has not yet arrived. The whole guidance depends on that lag clearing.

The price the market is asking

Here the setup is not a cheap one, which changes what the guidance is worth. The market capitalization is roughly DKK 9 billion against DKK 201.8 million of net profit — a multiple in the low-40s on a business growing around 10%. That is the price of a high-quality compounder, and it means the re-acceleration has to keep landing quarter after quarter rather than merely arrive once. Notably, ChemoMetec declares no dividend; it is instead buying back its own shares out of cash flow, a vote of confidence from management but not a yield you can count on.

There is also an access problem worth naming for a U.S. investor. This is a Danish small-cap that trades on Nasdaq Copenhagen, so a U.S. retail account typically reaches it only through over-the-counter or international listings, adding currency exposure of exactly the kind that shaved the last year's reported growth. The stock is a real operating story, but it is not a frictionless one to own.

One independent snapshot captures the market's mood: the share price sits near DKK 510, three analysts cover it with an average twelve-month target of around DKK 638, and the current price already reflects the stale worry of biotech capital-spending freezes. The step from DKK 510 to the target is a modest re-rating, not a dramatic recovery — the recovery itself must be earned in the reported numbers.

The number that decides it

ChemoMetec has the machinery of a turn: a still-fat 55% EBITDA margin, a product cycle more than doubling, and guidance that finally asks the market to pay for better days. But the one metric that would make the turn "financially undeniable" is the one that has not yet moved — growth in recurring consumables behind the new installed base. It fell 4% last year, and the U.S., its largest market, is the section that must thaw. Until consumables re-accelerate, this is a company telling you it is better than the tape shows, at a price that already treats the improvement as if it were here.

The honest reading is a watch, not a sprint to buy. The guidance is credible but unproven, and at roughly 44 times trailing earnings the market is not paying you to be early. The first real check is the half-year report early next year, when you can see whether the reagent revenue finally arrives behind all those new XcytoMatic placements, and whether the U.S. cell-therapy freeze is lifting. Until that repeating revenue turns positive, the stock is pricing a turn the operating data has not yet delivered.